Drug Target Review

APRIL 9, 2024

Among other discoveries, the group developed inhibitors of the ATR kinase and showed their potential for cancer therapy. These compounds were later licensed to the pharmaceutical industry for clinical development.

RNA 64

RNA Cell Biology Clinical Development DNA 64

The Pharma Data

JANUARY 12, 2021

Boehringer Ingelheim has announced it has signed a collaboration and licensing deal with Enara Bio to advance novel targeted cancer immunotherapies. According to Enara, Dark Antigens can potentially be developed as targets for immunotherapy agents. Michael Vi/Shutterstock.

Research 52

Research Licensing Licensing Vaccine 52

The Pharma Data

AUGUST 10, 2020

Novavax is partnering up with the Serum Institute of India Private Limited (SIIPL) in a licensing deal to development and marketing of up to one billion doses of its potential recombinant COVID-19 vaccine candidate, NVX?CoV2373.

Vaccine 52

Vaccine Licensing Licensing Clinical Development 52

The Pharma Data

JANUARY 25, 2021

26, 2021 /PRNewswire/ — Asieris Pharmaceuticals announced today that the company has entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to exclusively register and commercialize Hexvix® in Mainland China and Taiwan. SHANGHAI , Jan. ” About Photocure ASA.

Licensing 40

Licensing Licensing Clinical Development Pharmaceutical Companies 40

The Pharma Data

JUNE 7, 2023

Acuitas’ proprietary LNP technology is used in multiple vaccines and therapeutics in clinical development and was also used in some of the COVID-19 vaccines that were approved and administered to people in 180 countries. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery.

Therapies 40

Therapies RNA Licensing Licensing 40

The Pharma Data

DECEMBER 21, 2020

Legend will receive $75 million from J&J as a clinical development-based milestone payment, per a 2017 collaboration pact.

Therapies 40

Therapies Licensing Licensing Clinical Development 40

Conversations in Drug Development Trends

FEBRUARY 21, 2024

During clinical development, new chemical entities (NCEs) require an absorption, metabolism, and excretion (AME) study.

Clinical Trials 80

Clinical Trials Pharmacy Clinical Pharmacology FDA 80

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. AbbVie has initiated a Phase I clinical trial of the antibody, and it will conduct the initial clinical program in the U.S.

Licensing 52

Licensing Licensing Pharmacokinetics Clinical Trials 52

The Pharma Data

FEBRUARY 14, 2022

“This virus shows how interconnected we all are and I am proud that Belgium –and other EU countries – are now collaborating to build vaccine capacity everywhere,” said Meryame Kitir, Minister of Development Cooperation and Urban Policy of Belgium. We are opening the door to better health and wellbeing for our people.”. “At

Vaccine 52

Vaccine Licensing Licensing Science 52

The Pharma Data

JANUARY 17, 2021

The companies announced in January 2019 a collaboration agreement to develop, manufacture and commercialize SPR206 in the Territory. SPR206 is in clinical development as an innovative option for the treatment of multi-drug resistant (MDR) Gram-negative bacterial infections. SHANGHAI , Jan. SHANGHAI , Jan.

Clinical Trials 52

Clinical Trials Clinical Development Pharmacokinetics Pharmaceutical Companies 52

The Pharma Data

APRIL 27, 2022

We plan to discuss these data with health authorities, and we will continue to expand our tislelizumab clinical development program in pursuit of novel, synergistic combinations with the ultimate goal of extending survival for more patients.”. About Novartis Novartis is reimagining medicine to improve and extend people’s lives.

Treatment 52

Treatment Clinical Development Therapies Clinical Trials 52

The Pharma Data

FEBRUARY 22, 2021

(Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. vice president of immunology at Lilly.

Clinical Development 40

Clinical Development Small Molecule Clinical Trials Immune Response 40

The Pharma Data

APRIL 14, 2021

Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. Genentech, a member of the Roche group, and Novartis Pharmaceuticals Corporation work together to develop and co-promote Xolair. indications.

FDA Approval 52

FDA Approval Clinical Development FDA Treatment 52

LifeSciVC

JULY 17, 2024

Fortunately, AbbVie felt the same way, which is why we initiated discussions to in-license AbbVie’s most promising CF pipeline programs. We obtained exclusive worldwide rights to develop and commercialize multiple clinical-stage compounds, including two that have completed Phase 2 studies.

Clinical Research 44

Clinical Research Disease Research Clinical Trials 44

The Pharma Data

OCTOBER 18, 2020

Dr. Berk, commented “I am excited to join the Board of Inflection Biosciences as it advances its novel PIM/PI3K inhibitor, IBL-202, towards clinical development for unmet needs in B-cell malignancies and other cancers.”. Dr. Berk most recently has served as a consultant to several companies developing oncology therapies.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

Drug Target Review

NOVEMBER 15, 2024

As Novo Nordisk UK’s head of clinical development during the COVID pandemic, I led our efforts in the UK to ensure research continuity in metabolic diseases amidst a global focus on COVID-19. The disruptions caused by the pandemic transformed how research was conducted.

Science 52

Science Clinical Development Research Regulations 52

The Pharma Data

DECEMBER 8, 2020

technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnering. The company’s validated, proprietary F.I.R.S.T

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

NOVEMBER 23, 2020

At Ultimovacs, he will lead all business and corporate development efforts and continue to maintain and foster connections with leading biotechnology and pharmaceutical companies. “In Mr. Berkien is currently a board member of the Nordic Pharma Licensing Group.

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

Agency IQ

JULY 26, 2024

Postapproval manufacturing changes for biological products During clinical development or following a product’s approval , sponsors and/or manufacturers may identify the need for a change in the product, production process, quality controls, equipment, facilities, responsible personnel, or labeling.

Biosimilars 40

Biosimilars Science FDA Production 40

The Pharma Data

OCTOBER 6, 2021

Janssen is now moving its dengue program into clinical development. We look forward to working with our collaborators to accelerate clinical development.”. “As Global Head of Global Public Health R&D at Janssen Research & Development, LLC. Janssen Pharmaceutica, N.V.

Virus 52

Virus Clinical Development Science Disease 52

PPD

MAY 7, 2024

Further, the new regulation encourages HTDs to anticipate PICO scoping in their current clinical development strategy, fostering collaboration between internal and external stakeholders at both global and national levels.

Regulations 52

Regulations Pharmaceutical Companies International Pharmaceuticals 52

Drug Target Review

FEBRUARY 1, 2024

In other cases, well-established biomarker profiles enable patient enrichment strategies in early-stage clinical development. We have been hard at work for two-and-a-half years on developing a precision treatment for GRIN-related disorders, a genetically defined developmental epileptic encephalopathy.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

The Pharma Data

AUGUST 6, 2020

AstraZeneca reached a licensing deal with Chinese firm BioKangtai to help provide its adenovirus vector-based COVID-19 vaccine candidate, created by the University of Oxford, to China, AstraZeneca said (Chinese) in a social media post on Thursday. China has several home-grown COVID-19 vaccines in clinical development.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

JANUARY 10, 2021

Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Supply Trials 52

The Pharma Data

JUNE 28, 2021

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Xofigo is currently under further evaluation in a broad clinical development program in prostate cancer and beyond.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

The Pharma Data

JANUARY 21, 2021

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 18, 2021

Gilead has been encouraged by early clinical data generated for each of the three programs. By concluding in early to all three programs now, Gilead and Arcus are suitable to accelerate the clinical development and advancement of these clinical- stage motes and grease the disquisition of treatment combinations across the portfolios.

Research 52

Research Clinical Development Small Molecule Packaging 52

The Pharma Data

NOVEMBER 23, 2020

Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to regain compliance with the continued listing standards by the end of the extension period, the ability to engage in a potential acquisition, merger, reverse merger, other business combination, sales of assets, (..)

Compliance 52

Compliance Licensing Licensing Clinical Trials 52

The Pharma Data

DECEMBER 13, 2020

MacroGenics , based in Rockville, Maryland, has a target action date of December 18 for its Biologics License Application (BLA) for margetuximab in combination with chemotherapy for patients with metastatic HER2+ breast cancer. Zai Lab is leading clinical development in its territory. “We Read on for this week’s.

FDA 52

FDA Biosimilars Clinical Trials Licensing 52

The Pharma Data

NOVEMBER 25, 2020

technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The Company’s validated, proprietary F.I.R.S.T

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

JANUARY 4, 2021

The program was licensed to Allergan in April 2016 , and Allergan was acquired by AbbVie in May 2020. Sosei Heptares will now conduct a full internal review to determine a strategy for the further development and re-partnering of the program. . ” About the License Agreement. TOKYO and CAMBRIDGE, England , Jan.

Licensing 40

Licensing Licensing Clinical Trials Disease 40

The Pharma Data

MARCH 16, 2021

The potential of centrally acting COMT inhibitors has not yet been evaluated in the clinic due to the unavailability of such compounds. In partnering with the Lieber Institute, Boehringer Ingelheim has in-licensed preclinical pipeline candidates, representing a first-in-class approach for targets in neuropsychiatric disorders.

Licensing 52

Licensing Licensing Research Laboratories Treatment 52

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. Boehringer Ingelheim will advance the programs further and bring promising candidates into non-clinical and clinical development.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. for its cGMP-compliant CHOSOURCE platform. in Mainland China.

Licensing 52

Licensing Licensing DNA Vaccine 52

Metabolite Tales Blog

NOVEMBER 17, 2022

Figure 3: Roquinimex (linomide) Clinical development of both laquinimod and roquinimex was halted due to serious cardiovascular events. Studies in non-clinical species raised no obvious red flags of this clinical outcome. Teva Pharmaceuticals licensed laquinimod from Active Biotech. This was unexpected.

International 52

International Licensing Licensing Treatment 52

The Pharma Data

JANUARY 19, 2021

technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The Company’s validated, proprietary F.I.R.S.T

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. Each of the companies met strict criteria that includes assets in clinical development, an industry-leading platform and in-house manufacturing capabilities. “We Photo courtesy of Bayer.

Therapies 52

Therapies Licensing Licensing Pharmaceuticals 52